Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 4
2004 7
2005 4
2006 7
2007 12
2008 6
2009 2
2010 6
2011 8
2012 11
2013 8
2014 12
2015 14
2016 12
2017 19
2018 13
2019 13
2020 13
2021 17
2022 19
2023 21
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

200 results

Results by year

Filters applied: . Clear all
Page 1
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M. Fischer K, et al. Among authors: langerak aw. N Engl J Med. 2019 Jun 6;380(23):2225-2236. doi: 10.1056/NEJMoa1815281. Epub 2019 Jun 4. N Engl J Med. 2019. PMID: 31166681
Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL.
Agathangelidis A, Chatzidimitriou A, Chatzikonstantinou T, Tresoldi C, Davis Z, Giudicelli V, Kossida S, Belessi C, Rosenquist R, Ghia P, Langerak AW, Davi F, Stamatopoulos K; ERIC, the European Research Initiative on CLL. Agathangelidis A, et al. Among authors: langerak aw. Leukemia. 2022 Aug;36(8):1961-1968. doi: 10.1038/s41375-022-01604-2. Epub 2022 May 25. Leukemia. 2022. PMID: 35614318 Free PMC article. Review.
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M. Goede V, et al. Among authors: langerak aw. N Engl J Med. 2014 Mar 20;370(12):1101-10. doi: 10.1056/NEJMoa1313984. Epub 2014 Jan 8. N Engl J Med. 2014. PMID: 24401022 Free article. Clinical Trial.
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, Verdugo M, Wu J, Punnoose EA, Jiang Y, Wang J, Boyer M, Humphrey K, Mobasher M, Kipps TJ. Kater AP, et al. Among authors: langerak aw. J Clin Oncol. 2019 Feb 1;37(4):269-277. doi: 10.1200/JCO.18.01580. Epub 2018 Dec 3. J Clin Oncol. 2019. PMID: 30523712 Free article. Clinical Trial.
Editorial: The promise of immunogenetics for precision oncology.
Vlachonikola E, Langerak AW, Rosenquist R, Chatzidimitriou A. Vlachonikola E, et al. Among authors: langerak aw. Front Oncol. 2023 Aug 9;13:1252189. doi: 10.3389/fonc.2023.1252189. eCollection 2023. Front Oncol. 2023. PMID: 37621683 Free PMC article. No abstract available.
High-Throughput immunogenetics for precision medicine in cancer.
Agathangelidis A, Vlachonikola E, Davi F, Langerak AW, Chatzidimitriou A. Agathangelidis A, et al. Among authors: langerak aw. Semin Cancer Biol. 2022 Sep;84:80-88. doi: 10.1016/j.semcancer.2021.10.009. Epub 2021 Oct 30. Semin Cancer Biol. 2022. PMID: 34757183 Free article. Review.
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL.
van der Straten L, Stege CAM, Kersting S, Nasserinejad K, Dubois J, Dobber JA, Mellink CHM, van der Kevie-Kersemaekers AF, Evers LM, de Boer F, Koene HR, Schreurs J, van der Klift M, Velders GA, van der Spek E, van der Straaten HM, Hoogendoorn M, van Gelder M, Posthuma EFM, Visser HPJ, Houtenbos I, Idink CAM, Issa DE, Dompeling EC, van Zaanen HCT, Veelken JH, Levenga H, Tick LW, Terpstra WE, Tonino SH, Westerweel PE, Langerak AW, Kater AP, Levin MD. van der Straten L, et al. Among authors: langerak aw. Blood. 2023 Sep 28;142(13):1131-1142. doi: 10.1182/blood.2023020195. Blood. 2023. PMID: 37363833
Clonotype definitions for immunogenetic studies: proposals from the EuroClonality NGS Working Group.
Sofou E, Vlachonikola E, Zaragoza-Infante L, Brüggemann M, Darzentas N, Groenen PJTA, Hummel M, Macintyre EA, Psomopoulos F, Davi F, Langerak AW, Stamatopoulos K. Sofou E, et al. Among authors: langerak aw. Leukemia. 2023 Aug;37(8):1750-1752. doi: 10.1038/s41375-023-01952-7. Epub 2023 Jun 30. Leukemia. 2023. PMID: 37391484 Free PMC article. No abstract available.
200 results